Business
New contract with Metir plc
Aptamer Group plc has signed a new contract with Metir plc to develop Optimer binders for rapid detection of Cryptosporidium parvum oocysts in Metir's Pathogen Detector platform. This agreement builds upon a prior collaboration announced on June 14, 2024, and aims to create high-affinity binders for real-time water quality monitoring, delivering results in minutes compared to days with conventional methods. The staged program will focus on feasibility, isolation, and optimization, with proof-of-concept data expected within three months, representing a key milestone for Metir's Pathogen Detector, potentially leading to initial trials by UK water companies. Disclaimer*
About this update from Aptamer Group Plc
11 September 2025 Aptamer Group plc ("Aptamer", the "Company" or the "Group") New contract with Metir plc Development of Optimer® binders for rapid Cryptosporidium detection in the next-generation pathogen monitoring platform Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new contract with Metir plc (AIM: MET), the leading global provider of mobile and point-of-use water and environmental testing technology. The agreement covers the development of Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir's Pathogen Detector platform. Further to the Company's announcement on 14 June 2024 regarding collaboration with Metir on pathogen detection, the new agreement involves the creation of novel high-affinity binders for integration into Metir's real-time monitoring device. This system is designed to provide continuous water quality monitoring and early detection of contamination within minutes, compared with conventional laboratory testing that can take several days. The collaboration highlights the adaptability of Aptamer Group's Optimer® technology in delivering robust, synthetic binders with high specificity and stability for real-world deployment. Optimers offer a secure, scalable supply chain and can be tailored for multiplexed detection of multiple pathogens, expanding potential applications into broader environmental and healthcare monitoring markets. The staged programme will deliver feasibility, isolation and optimisation work, with proof-of-concept data expected within three months. This represents one of the final technical milestones to advance Metir's Pathogen Detector beyond the prototype stage, with possible initial trials by UK water companies anticipated once development is complete. Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are pleased to be working with Metir on this important programme. Our Optimer® technology is ideally suited for Cryptosporidium detection, and we look forward to supporting the development of this pathogen monitoring platform." Bob Moore, Executive Chairman and Chief Executive Officer of Metir, said: "This agreement marks another step forward in Metir's strategy to deliver next-generation, real-time water monitoring solutions. The Group's close collaboration with Aptamer Group strengthens our position in protecting public health, especially in water purity, through innovative detection technology." - Ends - For further information, please contact: Aptamer Group plc Dr Arron Tolley, Chief Executive Officer +44 (0) 1904 217 404 SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat +44 (0) 20 3368 3550 Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker +44 (0) 20 3657 0050 Northstar Communications Limited - Investor Relations Sarah Hollins +44 (0) 113 730 3896 Reach announcement This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach. About Aptamer Group Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies. Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue. Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK. To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/